Showing 1236 results
-
Press Release /China National Medical Products Administration (NMPA) approval reinforces that Cosentyx® (secukinumab) is safe and effective for children and adults with psoriasis Moderate-to-severe plaque…
-
Press Release /Results from year two of the pivotal Phase III KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one1,2 In key fluid-related…
-
Ad-hoc Releases /Ad hoc announcement pursuant to Art. 53 LR FDA concluded that OAV-101 intrathecal (IT) clinical program may proceed based on data from nonclinical toxicology study New Phase 3 STEER study will…
-
Ad-hoc Releases /Annonce événementielle selon l’art. 53 RC Chiffre d’affaires net du T2 en progression de +9% (tcc1, +14% USD): Pharmaceuticals: cette unité d’affaires (UO) a vu son chiffre d’affaires progresser de…
-
Ad-hoc Releases /Ad-hoc-Mitteilung gemäss Art. 53 KR Der Nettoumsatz wuchs im zweiten Quartal um +9% (kWk¹, +14% USD): Die Geschäftseinheit Pharmaceuticals legte +12% (kWk, +18% USD) zu mit…
-
Ad-hoc Releases /Ad hoc announcement pursuant to Art. 53 LR Net sales in Q2 grew +9% (cc¹, +14% USD): Pharmaceuticals BU grew +12% (cc, +18% USD) with continued strong growth from Entresto (+46% cc), Cosentyx (+21…
-
Press Release /Novartis and the Novartis US Foundation to join forces with Thurgood Marshall College Fund, Morehouse School of Medicine, 26 other Historically Black Colleges, Universities and Medical Schools and…
-
Press Release /REACH3 data show Jakavi significantly improved overall response rate (ORR) at week 24 (49.7% vs. 25.6%) with a higher best overall response rate (76.4% vs. 60.4%) vs. best available therapy, among…
-
Ad-hoc Releases /Basel, June 28, 2021 — Novartis announced today the appointment of Rob Kowalski, Pharm.D., Global Head Regulatory Affairs and US Head of Drug Development as Chief People & Organization Officer.…
-
Press Release /Pemetrexed is indicated for patients with non-squamous Non-Small Cell Lung Cancer (NSCLC), who represent over 3 in 4 patients with lung cancer1 New ready-to-dilute format and 1,000 mg strength…